中药干预新型冠状病毒肺炎的临床研究  

Clinical study of traditional Chinese medicine against Corona Virus Disease 2019

作　　者：柴可群[1] 黄飞华[1] 李亚平[1] 周颖[1] 陈扬波[1] 胡旭 浦锦宝[1] 何秀英[1] 饶先林[1] 李娜[1] 刘忻颖 翁卫东[1] 余平[1] 万燕丽 袁拯忠[2] 林晓阳 陈礼平[4] 彭春仙[5] 潘光强[6] 陈小弟[7] 尹丽 CHAI Ke-qun;HUANG Fei-hua;LI Ya-ping;ZHOU Ying;CHEN Yang-bo;HU Xu;PU Jin-bao;HE Xiu-ying;RAO Xian-lin;LI Na;LIU Xin-ying;WENG Wei-dong;YU Ping;WAN Yan-li;YUAN Zheng-zhong;LIN Xiao-yang;CHEN Li-ping;PENG Chun-xian;PAN Guang-qiang;CHEN Xiao-di;YIN Li(Tongde Hospital of Zhejiang Province,Hangzhou 310000,China;The First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China;The First People’s Hospital of Wenling City,Wenling 317500,China;The Traditional Chinese Medicine Hospital of Lishui City,Lishui 323000,China;The People’s Hospital of Quzhou City,Quzhou 324000,China;The People’s Hospital of Ruian City,Ruian 325200,China;The Central Hospital of Yiwu City,Yiwu 322000,China;The Fourth Affiliated Hospital of Zhejiang University School of Medicine,Yiwu 322000,China)

机构地区：[1]浙江省立同德医院,杭州310000 [2]温州医科大学附属第一医院,温州325000 [3]温岭市第一人民医院,温岭317500 [4]丽水市中医院,丽水323000 [5]衢州市人民医院,衢州324000 [6]瑞安市人民医院,瑞安325200 [7]义乌市中心医院,义乌322000 [8]浙江大学医学院附属第四医院,义乌322000

出　　处：《中华中医药杂志》2021年第12期7458-7462,共5页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：浙江省科技厅重点研发应急攻关项目(No.2020C03127)。

摘　　要：目的:通过中药抗新型冠状病毒肺炎(COVID-19)的临床研究,提供中药抗COVID-19的有效制剂。方法:选取浙江省7家医院2020年2月3日至3月19日的150例COVID-19患者,随机分为中西医组109例,西医组41例。中西医组在西医组治疗基础上根据疾病分期及中医证型分别给予新冠肺炎1、2、3号方治疗,比较两组患者的中医症候积分、体温复常时间、核酸转阴时间、肺部影像积分、MuLBSTA积分及临床治愈率。结果:中西医组治疗前后中医症候积分差值显著高于西医组(P<0.01);中西医组的肺部影像积分与MuLBSTA积分的治疗前后差值均较西医组显著增加(P<0.01,P<0.05);中西医组的临床治愈率显著高于西医组(P<0.05)。结论:中药联合西医治疗能有效减轻COVID-19患者的临床症状,改善肺部感染情况,提高临床治愈率,值得推广应用。Objective: To provide the effective traditional Chinese medicine against Corona Virus Disease 2019(COVID-19) through the clinical study of anti-COVID-19. Methods: A total of 150 patients with COVID-19 from 7 hospitals in Zhejiang province from February 3, 2020 to March 19, 2020 were screened, they were randomly divided into the TCM and western medicine group(109 cases), the western medicine group(41 cases). On the basis of the treatment in the western medicine group, COVID-19 No.1, No.2 and No.3 TCM compound were given to the TCM and western medicine group according to the disease stage and TCM syndrome type, respectively. The decrease value of TCM syndrome score, the time of temperature to normal, the time of nucleic acid to negative, lung image score, MuLBSTA score and clinical cure rate of the two groups of patients were compared. Results: After treatment, the TCM syndrome scores in TCM and western medicine group were significantly decreased compared with that in western medicine group(P<0.01). The difference of pulmonary image score and MuLBSTA score before and after treatment were increased compared with the western medicine group(P<0.01, P<0.05). The clinical cure rate of TCM and western medicine group was higher than that of western medicine group(P<0.05). Conclusion: Traditional Chinese medicine and western medicine can significantly reduce the clinical symptoms of patients, improve pulmonary infection and clinical cure rate, worthy of promotion and application.

关 键 词：新型冠状病毒肺炎 中医治疗 疫病 传染病 新冠肺炎1号方 新冠肺炎2号方 新冠肺炎3号方 

分 类 号：R259[医药卫生—中西医结合]